The Reaction Mechanism for CD38. A Single Intermediate Is Responsible for Cyclization, Hydrolysis, and Base-Exchange Chemistries
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Human recombinant CD38 catalyzes the formation of both cyclic ADP-ribose and ADP-ribose products from NAD+ and hydrolyzes cyclic ADP-ribose to ADP-ribose. The corresponding GDP products are formed from NGD+. The enzyme was characterized by substrate and inhibition kinetics, exchange studies, rapid-quench reactions, and stopped-flow-fluorescence spectroscopy to establish the reaction mechanism and energetics for individual steps. Noncyclizable substrates NMN+ and nicotinamide-7-deaza-hypoxanthine dinucleotide (7-deaza NHD+) were rapidly hydrolyzed by the enzyme. The kcat for NMN+ was 5-fold higher than that of NAD+ and has the greatest reported kcat of any substrate for CD38. 7-deaza-NHD+ was hydrolyzed at approximately one-third the rate of NHD+ but does not form a cyclic product. These results establish that a cyclic intermediate is not required for substrate hydrolysis. The ratio of methanolysis to hydrolysis for cADPR and NAD+ catalyzed by CD38 increases linearly with MeOH concentration. Both reactions produce predominantly the beta-methoxy riboside compound, with a relative nucleophilicity of MeOH to H2O of 11. These results indicate the existence of a stabilized cationic intermediate for all observed chemistries in the active site of CD38. The partitioning of this intermediate between cyclization, hydrolysis, and nicotinamide-exchange unites the mechanisms of CD38 chemistries. Steady-state and pre-steady-state parameters for the partition and exchange mechanisms allowed full characterization of the reaction coordinate. Stopped-flow methods indicate a burst of cGDPR formation followed by the steady-state reaction rate. A lag phase, which was NGD+ concentration dependent, was also observed. The burst size indicates that the dimeric enzyme has a single catalytic site formed by two subunits. Pre-steady-state quench experiments did not detect covalent intermediates. Nicotinamide hydrolysis of NGD+ precedes cyclization and the chemical quench decomposes the enzyme-bound species to a mixture of cyclic and hydrolysis products. The time dependence of this ratio indicated that nicotinamide bond-breakage occurs 4 times faster than the conversion of the intermediate to products. Product release is the overall rate-limiting step for enzyme reaction with NGD+.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jackson, D. G., & Bell, J. I. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.7.2811 · Cited by 343
Cited by
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
NAD+ metabolism in health and disease
Belenky, P., Bogan, K. L., & Brenner, C. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.11.006 · Cited by 981
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899
“Enzymes Km for NAD Sir2 100 M (242) SIRT1 150–200 M (243) SIRT2 100 M (243) SIRT3 280 M (244) SIRT4 Unknown SIRT5 Unknown SIRT6 Unknown SIRT7 Unknown PARP1 20–60 M (245, 246) PARP2 130 M (246) CD38 15–25 M (85, 153, 247) Endocrine Reviews, April 2010, 31(2):194–223 edrv.”
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790
“Second, CD38 may metabolize NMN, but not NR, Cell Metabolism 30, October 1, 2019 631 into NAM, which is able to cross the plasma membrane (Camacho-Pereira et al., 2016; Grozio et al., 2013; Sauve et al., 1998).”
Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going?
Hassa, P. O., Haenni, S. S., Elser, M., & Hottiger, M. O. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00040-05 · Cited by 682
NAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627
Quantitative Analysis of NAD Synthesis-Breakdown Fluxes
Liu, L., Su, X., Quinn, W. J., Hui, S., Krukenberg, K., Frederick, D. W., Redpath, P., Zhan, L., Chellappa, K., White, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.018 · Cited by 564
The dynamic regulation of NAD metabolism in mitochondria
Stein, L. R., & Imai, S.-I. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.005 · Cited by 535
Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers
Lee, H. C. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.317 · Cited by 433
Self-citationThe Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Hogan, K. A., Chini, C. C. S., & Chini, E. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01187 · Cited by 337
TRPM2 Functions as a Lysosomal Ca2+-Release Channel in β Cells
Lange, I., Yamamoto, S., Partida-Sanchez, S., Mori, Y., Fleig, A., & Penner, R. (2009) · Science Signaling · doi:10.1126/scisignal.2000278 · Cited by 295
New functions of a long‐known molecule: Emerging roles of NAD in cellular signaling
Ziegler, M. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01187.x · Cited by 289
NAD + metabolism: A therapeutic target for age-related metabolic disease
Mouchiroud, L., Houtkooper, R. H., & Auwerx, J. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.789479 · Cited by 193
“Small molecule CD38 inhibitors (or CD157 inhibitors if identified) may circumvent this problem, but further insights in the NAD+ accumulation and trafficking are required (Sauve et al., 1998; Sauve & Schramm, 2002).”
BackgroundGrozio, A., Sociali, G., Sturla, L., Caffa, I., Soncini, D., Salis, A., Raffaelli, N., De Flora, A., Nencioni, A., & Bruzzone, S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.470435 · Cited by 158
“The ectoenzyme CD38 degrades NMN and generates NAM (38), which can cross the plasma membrane (39) and fuel NAD synthesis via NAMPT activity.”
BackgroundNAD+ flux is maintained in aged mice despite lower tissue concentrations
McReynolds, M. R., Chellappa, K., Chiles, E., Jankowski, C., Shen, Y., Chen, L., Descamps, H. C., Mukherjee, S., Bhat, Y. R., Lingala, S. R., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2021.09.001 · Cited by 112
BST1 regulates nicotinamide riboside metabolism via its glycohydrolase and base-exchange activities
Yaku, K., Palikhe, S., Izumi, H., Yoshida, T., Hikosaka, K., Hayat, F., Karim, M., Iqbal, T., Nitta, Y., Sato, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27080-3 · Cited by 76
Ruggieri, S., Orsomando, G., Sorci, L., & Raffaelli, N. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.02.021 · Cited by 71
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model
Sociali, G., Raffaghello, L., Magnone, M., Zamporlini, F., Emionite, L., Sturla, L., Bianchi, G., Vigliarolo, T., Nahimana, A., Nencioni, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6502 · Cited by 70
Metadata
- Authors
- Sauve, A. A., Munshi, C., Lee, H. C., & Schramm, V. L.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1998-08-29
- Volume
- 37
- Issue
- 38
- Pages
- 13239-13249
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2000638509
- Cited by
- 120
- References
- 1
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.